Pandemic & Infectious Disease — 2026-03-29
Measles cases in the U.S. continue their upward climb toward a 34-year high, while a new study links record-breaking dengue outbreaks in Peru to climate-driven extreme weather — with implications for Florida. Meanwhile, Pfizer and Valneva's Lyme disease vaccine candidate is advancing toward FDA approval after Phase 3 trial data showed 73.2% efficacy, and *The Lancet* published a major commentary urging world leaders to elevate spillover prevention ahead of the 2026 UN High-Level Meeting on pandemic preparedness.
Pandemic & Infectious Disease — 2026-03-29
Active Outbreak Tracker
Measles — United States (Ongoing, 34-Year High)
- Status: Case counts trending toward a 34-year high; weekly updates being tracked by CDC and NBC News.
- Key Development: NBC News's live tracker, updated this week, shows measles case totals continuing to rise in 2026 on the heels of a surge that began in 2025. Multiple states remain active outbreak zones. Vaccination gaps in certain communities are a key driver of sustained transmission.
- Response: CDC is updating its measles data page weekly and urging communities to close vaccination gaps. Health officials continue to monitor and report outbreak clusters at the state level.
Dengue Fever — Peru / Climate-Linked Threat to Florida
- Status: Record-breaking outbreak; study published this week linking it to El Niño-driven extreme weather.
- Key Development: A study published March 27, 2026, by The Invading Sea connects a historically severe dengue outbreak in Peru to climate-driven extreme weather events, including El Niño. Researchers say this has direct implications for Florida, where local dengue transmission could increase as warming trends intensify mosquito-borne disease risk.
- Response: Public health officials are being urged to incorporate climate modeling into dengue surveillance and preparedness. No formal CDC or WHO advisory has been issued for Florida specifically, but researchers are calling for increased vigilance.
Respiratory Viruses (COVID-19, Flu, RSV) — United States
- Status: Activity monitoring updated March 27, 2026; detailed state-level Rt estimates available.
- Key Development: CDC's Respiratory Illnesses Data Channel, updated March 27, 2026, reflects the latest national and state-level surveillance for COVID-19, influenza, and RSV. The March 2026 respiratory disease season outlook provides qualitative assessments of ongoing transmission trends across the country.
- Response: CDC's Center for Forecasting and Outbreak Analytics (CFA) continues publishing weekly Rt estimates to track epidemic trends state by state, enabling timely public health responses.
Vaccine & Treatment Pipeline
- VLA15 / "Lyme disease vaccine" (Pfizer & Valneva): Phase 3 VALOR trial ("Vaccine Against Lyme for Outdoor Recreationists") results announced March 23–26, 2026 show 73.2% efficacy after the fourth and final dose in individuals aged 5 and older. Pfizer announced it intends to seek FDA approval despite the trial's enrollment limitations due to fewer Lyme cases than expected. Doctors quoted by ABC News called the results "encouraging," and the vaccine candidate has received a new brand name as it advances toward regulatory review. Vax-Before-Travel notes that Lyme disease season is soon to spike in the Northeast, raising urgency for approval.
- Phase III TB Vaccines and MDR-TB Treatments (Multiple developers): Clinical Trials Arena reported March 24, 2026 that GlobalData epidemiologists project tuberculosis cases across 16 major markets will reach 4.5 million by 2033. Several Phase 3 trials for TB vaccines and multi-drug-resistant TB treatments are actively underway and represent a critical pipeline to watch.
- mRNA and Next-Generation Vaccines (Various Developers): The 2026 regulatory calendar continues to feature multiple Phase 3 data readouts and prospective FDA filings for infectious disease therapeutics and vaccines, per Contagion Live's forward-looking tracker. Key milestones span influenza, COVID-19 variants, and other priority pathogens throughout the year.
Expert Analysis
A major commentary published March 26, 2026 in The Lancet calls on world leaders to make spillover prevention a central pillar of the 2026 UN High-Level Meeting on pandemic prevention, preparedness, and response (PPPR). The authors argue that while the COVID-19 pandemic briefly elevated PPPR on the global political agenda, "attention has waned amid inflation, war, and challenges" in many regions. The piece emphasizes that preventing zoonotic spillover — the transmission of pathogens from animals to humans — remains critically underfunded and underweighted in global health policy compared to outbreak response.
The dengue-climate study published this week reinforces a growing body of expert concern about how extreme weather events are reshaping infectious disease geography. Researchers examining the Peru outbreak underscore that El Niño-associated flooding and heat created ideal conditions for Aedes aegypti mosquito proliferation, producing transmission dynamics that exceeded historical norms. The study's authors explicitly flag Florida as a geography where similar dynamics could take hold, citing overlapping climate vulnerabilities and existing local mosquito populations.
On the vaccine front, infectious disease physicians responding to Pfizer and Valneva's Lyme disease trial results noted that while the trial encountered challenges with lower-than-expected case counts — limiting statistical power — the 73.2% efficacy signal after four doses is "encouraging" and could provide meaningful protection as tick-borne illness surges in the Hudson Valley and broader Northeast United States. Experts quoted across multiple outlets emphasized that the vaccine fills a significant gap, as no licensed Lyme disease vaccine has been available in the U.S. for over two decades.
Global Health Security
UN High-Level Meeting on Pandemic Preparedness (2026): The Lancet commentary published this week argues that the upcoming UN High-Level Meeting on PPPR is a pivotal moment to institutionalize spillover prevention — particularly the regulation of wildlife trade and land-use practices linked to pathogen emergence. Authors warn that without explicit political commitments at this meeting, the world risks repeating the conditions that enabled COVID-19 and other zoonotic outbreaks.
CDC Epidemic Intelligence and Forecasting: CDC's Center for Forecasting and Outbreak Analytics continued its publication of state-level Rt estimates for COVID-19, influenza, and RSV as of this week, reinforcing the agency's real-time surveillance infrastructure as respiratory disease season progresses.
Global TB Burden and Pipeline Policy: With GlobalData projecting 4.5 million TB cases across 16 major markets by 2033, Clinical Trials Arena's March 2026 report highlights the importance of regulatory pathways for TB vaccines and MDR-TB treatments currently in Phase 3. The scale of the projected burden underscores TB's continued status as a critical global health security threat requiring sustained investment.
What to Watch Next
-
Pfizer/Valneva Lyme FDA Submission: With Phase 3 results now announced and Pfizer publicly committed to seeking FDA approval, the formal submission timeline is the next milestone to monitor — especially heading into the Northeast's peak tick season. Approval could fill a 20+ year gap in U.S. Lyme disease prevention.
-
UN High-Level Meeting on PPPR: The 2026 UN High-Level Meeting on pandemic prevention, preparedness, and response will be a defining moment for global health governance. Watch for whether spillover prevention and zoonotic risk reduction earn binding commitments, or remain aspirational language.
-
Climate-Dengue Nexus in Florida: The Peru study published this week opens a new line of scientific and policy inquiry into dengue risk in the continental U.S. Subsequent modeling work and potential CDC or Florida health department guidance will determine whether this becomes an active public health priority for the 2026 mosquito season.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Create your own signal
Describe what you want to know, and AI will curate it for you automatically.
Create SignalPowered by
